source Post navigation Virtual diabetes prevention program available – The Southern APhA 2025: GLP-1 Receptor Agonists vs SGLT2 Inhibitors Show Varied Benefit for Cardiovascular Outcomes in Patients With Diabetes – Pharmacy Times